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Abstract
Purpose: Radiotherapy, especially with charged particles, is sensitive to exe-
cutional and preparational uncertainties that propagate to uncertainty in dose
and plan quality indicators, e. g., dose-volume histograms (DVHs). Current ap-
proaches to quantify and mitigate such uncertainties rely on explicitly computed
error scenarios and are thus subject to statistical uncertainty and limitations
regarding the underlying uncertainty model. Here we present an alternative, an-
alytical method to approximate moments, in particular expectation value and
(co)variance, of the probability distribution of DVH-points, and evaluate its ac-
curacy on patient data.
Methods: We use Analytical Probabilistic Modeling (APM) to derive moments
of the probability distribution over individual DVH-points based on the proba-
bility distribution over dose. By using the computed moments to parameterize
distinct probability distributions over DVH-points (here normal or beta distri-
butions), not only the moments but also percentiles, i. e., α-DVHs, are com-
puted. The model is subsequently evaluated on three patient cases (intracranial,
paraspinal, prostate) in 30- and single-fraction scenarios by assuming the dose
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to follow a multivariate normal distribution, whose moments are computed in
closed-form with APM. The results are compared to a benchmark based on dis-
crete random sampling.
Results: The evaluation of the new probabilistic model on the three patient
cases against a sampling benchmark proves its correctness under perfect assump-
tions as well as good agreement in realistic conditions. More precisely, ca. 90% of
all computed expected DVH-points and their standard deviations agree within
1% volume with their empirical counterpart from sampling computations, for
both fractionated and single fraction treatments. When computing α-DVHs,
the assumption of a beta distribution achieved better agreement with empirical
percentiles than the assumption of a normal distribution: While in both cases
probabilities locally showed large deviations (up to ±0.2), the respective α-DVHs
for α = {0.05, 0.5, 0.95} only showed small deviations in respective volume (up to
±5% volume for a normal distribution, and up to 2% for a beta distribution). A
previously published model from literature, which was included for comparison,
exhibited substantially larger deviations.
Conclusions: With APM we could derive a mathematically exact description
of moments of probability distributions over DVH-points given a probability dis-
tribution over dose. The model generalizes previous attempts and performs well
for both choices of probability distributions, i. e., normal or beta distributions,
over DVH-points.
ii
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I. Introduction
Recent years have shown an increased interest in adequate, patient-specific uncertainty
quantification and mitigation for radiotherapy treatment planning both academically and
clinically (see, e. g., Refs. 1, 2, and references therein). This development is, on the one
hand, driven by emerging irradiation with particles and their characteristic sensitivity to
uncertainties.3,4 On the other hand, it is facilitated by fast-growing computational capabili-
ties that enable the computation of multiple dose scenarios with acceptable overhead.
Error dose scenarios are either computed as (1) worst case estimates, i. e., extreme real-
izations of the input uncertainty model which are used for robust optimization (as performed
and evaluated within Refs. 5–11), or (2) random samples from the probability distribu-
tion parameterizing the input uncertainty model12–17 for stochastic approaches. An explicit
derivation of probabilistic models remains the exception.18–22
Consequently, the analysis of plan uncertainty is based on the derived worst-case dose
distributions or “error bar”-distributions with their respective histograms,6,7,11,23 or statistical
moments13,18,21,22,24 as well as percentiles,14,15,17 according to the very optimization method
used in the overall planning workflow. This use of empirical uncertainty estimates, however,
exhibits limitations, in particular concerning statistical accuracy and the required recompu-
tations during optimization due to the changing pencil-beam weights. Further, they conceal
the inherent mathematical transformation from the input probability space (e. g. set-up and
range uncertainties) to the probability distribution over dose and the respective plan quality
indicator (QI). This aggravates their use in retrospective analyses and puts restrictions on
the choice of optimization method and objectives, because the sampling pipeline cannot be
inverted and/or efficiently differentiated.
Approaches which rigorously propagate the uncertainty may overcome these limitations.
Since they are able to provide analytical objectives, constraints, and derivatives, they can
introduce new mathematical simplifications and improve computational efficiency by ex-
ploiting the analytical formulation for both uncertainty quantification and mitigation with
probabilistic optimization approaches.18,22 Because such approaches are not susceptible to
statistical errors and the “curse of dimensionality” in scenario-based approaches, they deliver
stable and reproducible results also for complex uncertainty models. However, derivation of
such models is not trivial: Even if a model for dose probability is available, it still needs to
be propagated to the derived plan indicators by hand. Other approaches overcome this step
by re-sampling based on the derived dose uncertainty model.20,21
For DVH-points, analytical computation of moments of the probability distribution,
given a probability distribution over the dose, has been attempted before.25–27 However, Cu-
tanda Henríquez and Vargas Castrillón25 ,26 only provide a model for the expected value of
DVH-points with an upper bound on the DVHs’ standard deviation. Further, only simpli-
fied uncertainty models for the underlying dose distribution were assumed: while different
shapes of the distributions were evaluated, correlations between voxels were not modeled,
even though correlations having crucial impact on the higher moments of the depending
probability distribution.
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To derive a full model including correlations, this work will consequently not build on
previous attempts, but provide a fresh start to a general methodology to compute the ν-th
moments of the probability distribution over DVH-points. The goal is to derive a generally
applicable model for DVH-probabilities allowing arbitrary assumptions on the probability
distribution over the dose distribution.
To do so, first a closed-form description for the moments of the probability distribution
of DVH-points is derived. Then, these moments parameterize a probability distribution over
the respective DVH-point. To evaluate our approach, three patient cases are investigated
with statistical reference computations (using a large number of random dose samples from
the probability distribution over set-up and range errors in fractionated and non-fractionated
treatments). Along the lines of our validation campaign, we illustrate the shortcomings of
previous work and highlight where wide approximations regarding the correlation models as
exercised by Cutanda Henríquez and Vargas Castrillón27 render meaningful quantification
of DVH-probabilities impossible.
II. Materials & Methods
II.A. DVHs under uncertainty
II.A.1. Nominal computation
DVHs are cumulative histograms over the spatial dose distribution in a volume of interest
(VOI) v, here expressed as vector d ∈ RV+ with number of voxels V . Hence, for any given
dose parameter dˆ, a DVH-point DVH(dˆ;d) ∈ [0, 1] equals the fraction of the volume that
receives at least dose dˆ. It can be expressed as averaged Heaviside steps
DVH(dˆ;d) =
1
V
∑
i∈v
Θ(di − dˆ) , (1)
meaning that only voxels i with di ≥ dˆ contribute to the sum which is normalized by the
total voxel count V in v and thus yielding a fractional volume. Note that (without loss of
generality) we assumed that all voxels have similar volume.
II.A.2. Uncertainty analysis of DVHs
Uncertainty analysis of DVHs is mostly performed on an empirical basis through compu-
tation of error dose scenarios (among others Refs. 2, 3, 6, 13–15, 17, 21, 22, 24, 28, 29). This
enables the computation of a DVH for each dose scenario (which can be either a worst-case
scenario or a random sample), from which then worst-case estimates, empirical statistical
moments as well as quantiles of the probability distribution over DVH-points are derived.
For the purpose of this work, three forms of “statistical” DVHs will be of importance.
First, uncertainty of a DVH can be evaluated through the statistical moments of each DVH-
point, for example the expected/mean DVH and its standard deviation, which can be em-
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pirically determined from ns random dose samples ds as
DVH(dˆ) =
1
ns
ns∑
s=1
DVH(dˆ;ds) (2)
σDVH(dˆ) =
√√√√ 1
ns − 1
ns∑
s=1
[
DVH(dˆ;ds)−DVH(dˆ)
]2
. (3)
Secondly we discuss “α-DVHs”, which can be compactly expressed as
α-DVH(dˆ;d, α) = vα ⇔ P (DVH(dˆ;d) ≤ vα) = α (4)
where vα is the volume covered with a probability P (DVH(dˆ) ≥ vα) = α. Thus α-DVHs can
be used to give percentiles of the probability distribution of each DVH-point and, together
with the corresponding (1-α)-DVH, the respective confidence intervals. α-DVHs may be
computed with the empirical marginal quantile functions for the respective DVH-points.
Alternatively, α-DVHs are equal to iso-probability curves on the respective dose-volume
coverage map (DVCM) as proposed by Gordon and Siebers14. Such a DVCM assigns a
probability of coverage of each possible volume fraction for any dose threshold dˆ and can be
defined as
DVCM(dˆ, v;d) = P (DVH(dˆ;d) ≤ v) = FDVH(dˆ,d)(v) , (5)
where FDVH(dˆ,d)(v) is the cumulative distribution function (CDF) of the probability dis-
tribution over the respective DVH-point. Equation (5) can then be directly inserted into
Equation (4) such that the respective α-DVH is now the iso-curve at DVCM = α.
Note that such α-DVHs or DVCMs do not yield confidences or probabilities for the full
DVH but only over single DVH-points (i. e., they represent marginal quantiles and CDFs),
and hence do not generally represent naturally occuring DVH-scenarios.
II.B. Moments of the probability distribution over dose-volume
histograms
II.B.1. Analytical integration
If the probability distribution over the dose d has the multivariate CDF Fd, the ν-
th moment of the probability distribution of a transformation I(d) can be computed via
integration
E [I(d)ν ] =
∫
RV
I(d˜)νdFd(d˜) (6a)
=
∫
RV
I(d˜)νfd(d˜)dd˜ . (6b)
Moments of the probability distribution over a DVH may thus be explicitly calculated
by solving Equation (6) for I(d) = DVH(dˆ;d). For the first non-central moment, this yields
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E
[
DVH(dˆ;d)
]
=
∫
RV
1
V
∑
i∈v
Θ(d˜i − dˆ)fd(d˜)dd˜ (7a)
=
1
V
∑
i
∫ ∞
−∞
Θ(d˜i − dˆ)fdi(d˜i)dd˜i (7b)
=
1
V
∑
i
∫ ∞
dˆ
fdi(d˜i)dd˜i (7c)
=
1
V
∑
i
[
1− Fdi(dˆ)
]
. (7d)
Similar steps lead to the mixed non-central moment E
[
DVH(dˆp;d)DVH(dˆq;d)
]
:
E
[
DVH(dˆp;d)DVH(dˆq;d)
]
=
∫
RV
1
V 2
∑
il∈v
Θ(d˜i − dˆp)Θ(d˜l − dˆq)fd(dˆ)dd˜ (8a)
=
1
V 2
∑
il∈v
∫
R2
Θ(d˜i − dˆp)Θ(d˜l − dˆq)fdi;l(d˜i;l)dd˜i;l (8b)
=
1
V 2
∑
il∈v
∞∫
dˆp
∞∫
dˆq
fdi;l(d˜i;l)dd˜ldd˜i . (8c)
For the second non-central moment with p = q, i. e., E
[
DVH(dˆp;d)
2
]
, Equation (8c)
can be expressed with the marginal bivariate cumulative distribution function Fdi;l as
E
[
DVH(dˆ;d)2
]
=
1
V 2
∑
il∈v
[
1− Fdi;l
(
dˆ12
)]
, (9)
where 12 = (1, 1)T .
Together Equations (7), (8c) and (9) then give the (co)variance of DVH-points at dˆp
and dˆq using Cov [x, y] = E [xy]− E [x]E [y], i. e.,
Cov
[
DVH(dˆp;d),DVH(dˆq;d)
]
= E
[
DVH(dˆp;d)DVH(dˆq;d)
]
− E
[
DVH(dˆp;d)
]
E
[
DVH(dˆq;d)
]
(10)
which, in case of the variance of a DVH-point at dˆ, consequently reduces to
Var
[
DVH(dˆ;d)
]
= E
[
DVH(dˆ;d)2
]
− E
[
DVH(dˆ;d)
]2
. (11)
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Hence, for each point of a DVH for a VOI v, Equations (7) to (11) allow explicit
computation of the expected value and variance of a DVH as well as the covariance between
all DVH points, valid for any probability distribution over the dose d in v as long as its
univariate and bivariate marginal CDF can be evaluated.
While not explicitly evaluated in this work, similar steps can be taken to compute
higher moments to more accurately parameterize the underlying probability distribution.
This requires an expansion of the respective power of the sums of Heaviside steps with the
multinomial theorem and evaluation of multivariate probabilities of higher dimensionality.
We provide such a generalization in Appendix C.
II.B.2. Summary of previous work
A result similar to Equation (7) was already documented in literature,25 where it was
obtained by interpreting the computation of the DVH according to Equation (1) as a sum
of Bernoulli experiments: Each voxel i falls into the current DVH bin at dˆ with a probability
pi = P (di > dˆ) = 1 − Fdi(dˆ), where Fdi is the marginal CDF for di, and does not fall into
the bin with a probability 1 − pi. With the linearity of the expectation value one then can
directly derive Equation (7d).
The result proved to be applicable with different families of assumed probability dis-
tributions (i. e., Gaussian, triangular and rectangular/uniform).25,26 However, due to the
simplified uncertainty model using constant relative standard deviation and no correlation
between voxels, an exact computation of higher moments of a DVH-point’s probability dis-
tribution was not attempted.
II.C. Confidence bounds for DVH-points
II.C.1. Parameterization of the DVH probability distribution
Since Equations (7) to (11) provide expected value and covariance of any DVH-point,
one could possibly directly parameterize the probability distribution over the full DVH with
a multivariate normal distribution. This parameterization is, however, unphysical; since
DVH-points represent the fraction of a volume, their values are confined to the interval
[0, 1] in contrast to the infinite support of the multivariate normal distribution. Hence,
the probability distribution of a DVH point might be more “physically” represented by a
distribution supported only in the interval [0, 1], such as a beta distribution B(a, b) with
shape parameters a and b. The beta distribution is shortly characterized in Appendix A.
However, lacking a generalized multivariate form (for recent approaches on constructing
bivariate beta distributions see, e. g., Refs. 30, 31), B(a, b) may only be used to parameterize
the marginal distribution over a single DVH-point, not the full multivariate DVH.
Current approaches applying DVH confidences define these on a marginal by-point ba-
sis.14,15,17,29 Hence, quantifying probabilities over marginal DVH-points is in line with lit-
erature and enables comparability. Therefore, in this work, marginal probabilities will be
evaluated, based on the (unphysical) parameterization with normal distributions as well as
the more physical approach using a beta distribution whose shape parameters a and b are ob-
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tained from the respective DVH-point’s expectation value and variance with Equations (23)
and (24).
Using either a normal or beta distribution, one can directly compute DVCMs according
to Equation (5) or an α-DVH using
α-DVH(dˆ;d, α) = F−1
DVH(dˆ;d)
(α)
=
E
[
DVH(dˆ;d)
]
+
√
2 Var
[
DVH(dˆ;d)
]
erf−1(2α− 1) | normal
I−1α (a, b) | beta
,
(12)
where erf−1 denotes the inverse error function and I−1α represents the inverse of the regular-
ized incomplete beta-function.
II.C.2. Summary of previous work
A subsequent work27 to Refs. 25, 26 already formulated an analyitcal calculation of
α-DVHs as defined in Equation (4). In summary, their model is based on the definition of
a “binary random variable”27
Tα,dˆi =
{
1 P (di ≥ dˆ) > 1− α
0 P (di ≥ dˆ) ≤ 1− α
(13)
interpreted as “the volume receiving a dose greater than [dˆ] with a probability greater than
1−α”27. This interpretation then leads them to define Tα,dˆi = Θ
(
1− α− Fdi(dˆ)
)
which, in
analogy to Equation (4), translates to
α-DVHHC(dˆ;d, α) =
1
V
∑
i∈v
Tα,dˆi =
1
V
∑
i∈v
Θ
(
1− α− Fdi(dˆ)
)
. (14)
Equation (14) substantially differs from our result in Equation (12). This may be
attributed to disregarding correlation across voxels in their derivations or inconsistencies in
the definition of Tα,dˆi , which apparently does not describe a random variable per se, but
rather includes the evaluation of a probability—in this case the probability P (di − dˆ) of
uncertain dose di exceeding dˆ—which is not a random but a fixed value obtained from the
CDF over di. Since Equation (14) has only been tested with an assumed uncertainty model
and not been benchmarked against sample statistics,27 we incorporate Equation (14) in our
evaluations and discuss the Equation further in Section IV.
II.D. Dose Uncertainty Model
Evaluation of Equations (7), (10) and (11) or, in general, Equation (25) requires a model
for the probability distribution over dose d, such that its CDF can be evaluated. Note that
empirical CDFs as well as analytical/parameterized CDFs can be used.
II. Materials & Methods
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II.D.1. Gaussian model for the probability distribution over dose
For a first evaluation and validation of the new probabilistic computations, we assume
d ∼ N (µ,Σ) , (15)
i. e., the dose follows a multivariate normal distribution with mean dose µ and covariance Σ.
This choice of probability distribution cannot represent the true underlying probability dis-
tribution: First, the multivariate normal is supported on the full multidimensional real space,
while physical dose is bound to the positive orthant. And second, empirical evidence (e. g.
Refs. 6, 24) as well as heuristic considerations show that the respective distribution exhibits
considerable skewness and is consequently not part of the symmetric Gaussian family. Al-
ternatives to assumption (15) will be discussed in Section IV. As a first order approximation,
however, Equation (15) is well suited to study the probabilistic DVH-model, because on the
one hand, its univariate and bivariate probabilities can be calculated,32 which is sufficient to
compute an expected DVH and its (co)variance. On the other hand, evaluation on patient
cases with assumption (15) implicitly studies the impact of the inaccurate Gaussian dose
model on the evaluation of VOI-based dose statistics like DVHs under uncertainty. Further,
while for a single fraction treatment the non-Gaussian shape of the probability distribution
over dose is to be expected, under multiple fractions a more Gaussian-like shape may form
(for examples of voxel dose probability distributions see Refs. 6, 24).
II.D.2. Computation of dose uncertainty
The Gaussian dose model from Section II.D.1 requires mean µ and covariance Σ for
evaluation. E. g., these could be empirically estimated with sample mean and covariance of
a set of discrete error scenarios.
Since the motivation of this work is to build a fully analytical model (which also fa-
cilitates future use in optimization), we rely on computation of µ and Σ through APM
as introduced by Bangert et al.18. In previous works we could already show that APM
accurately models µ and σ =
√
diag(Σ),33 and that efficient application to patient data—
especially in the context of fractionation22—is possible. Wieser et al.34 further extended it to
biological optimization by demonstrating APMs applicability to intensity-modulated carbon
ion therapy planning.
APM acts as a probabilistic pencil-beam dose calculation algorithm inherently enabling
computation of moments of the probability distribution over the resulting dose. More exact,
APM represents the constituents of a pencil-beam algorithm as superpositions of Gaussian
functions (including the integrated depth dose, i. e., the Bragg peak), enabling propagation
of uncertainties through the dose calculation in closed-form via analytical integration (for a
detailed explanation see Ref. 18).
The accuracy of this approximation of the pencil-beam algorithm can, in principle, be
arbitrarily chosen by varying the number of Gaussian components, thus providing also a
nominal dose calculation algorithm for inverse treatment planning that is similar in quality
to common pencil-beam algorithms. As such, it is able to provide a dose influence matrix
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D ∈ RV×B+ with number of voxels V and number of pencil-beams B generating the dose
d ∈ RV+ from the fluence vector w ∈ RB+ via the linear transformation
di =
∑
j
Dijwj . (16)
In Equation (16), i indexes voxels in the patient while j indexes pencil-beams.
Now, in addition to Equation (16), APM provides probabilistic analogs to Equation (16)
for moments of the probability distribution over d by enabling element-wise computation of
expectation value and (co)variance of elements of the dose influence matrix D. This allows
to represent the expected value of dose E [d] as a linear transformation
E [di] =
∑
j
E [Dij]︸ ︷︷ ︸
Dij
wj =
∑
j
Dijwj (17)
and the covariance in dose with a quadratic form
Cov [di, dl] =
∑
jm
Cov [Dij, Dlm]︸ ︷︷ ︸
Vijlm
wjwm =
∑
jm
Vijlmwjwm . (18)
Hence, one can denote D ∈ RV×B+ and V ∈ RV×B×V×B+ as expected dose influence matrix and
covariance influence tensor, respectively. While V is, in general, too large to be stored in
memory, the element-wise computation with APM allows on-the-fly evaluation of dependent
quantities, e. g. the variance or covariance of dose.
II.E. Validation and application of the model
The analytical probabilistic DVH-model will be evaluated on three patient cases, i. e., an
intracranial, a paraspinal, and a prostate case. Parameters used for planning and uncertainty
computations are laid out in Table 1. These cases were already evaluated in our previous
works.22,33,34 Furthermore, a detailed comparison of α-DVHs and DVCMs is exercised to
validate empirical percentiles against results from the respective quantile functions from
Equation (4) and the previous works by Cutanda Henríquez and Vargas Castrillón27.
II.E.1. Application on all cases using the fractionated treatment samples
For all three patient cases, empirical estimates DVH, σ¯2DVH are obtained by computing
100× 30 dose scenarios, i. e., 100 sampled treatment scenarios with 30 fraction each, based
on a Gaussian uncertainty model using the assumed setup and range errors from Table 1
as respective standard deviation with zero mean (compare to the description of the APM
uncertainty model in Ref. 18). Additionally, expected dose µ and covariance Σ within
the respective VOIs was also computed with APM (see Section II.D.2) for the same input
uncertainty model, and then fed into the herein presented DVH-models (by assuming a
multivariate normal distribution as described in Section II.D). This enabled comparison of
the sample statistics to a fully analytical method and serves as proof-of-concept of the derived
II. Materials & Methods
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model.
II.E.2. Full validation on the intracranial case with 5000 samples
As the intracranial case is the smallest one with lowest computational overhead, we
further computed 5000 realizations of single-fraction treatments. These will be used to
nearly eliminate statistical inaccuracy for benchmarking APM.
To further validate the analytical computation itself excluding inherent mismatch of
modeled and real probability distribution over dose, the analytically computed µ and Σ are
additionally used to create 5000 new dose samples under the assumption that dose actually
follows a multivariate normal distribution, i. e., their samples are drawn from the distribution
N (µ,Σ). From these samples, a second statistical estimate of the DVH is obtained. This
can be used to validate if the analytical computation is actually correct under the multivari-
ate normal assumption from Equation (15). Further, DVCMs and α-DVHs are computed
under the assumption of marginally normally distributed DVH-points and marginally beta
distributed DVH-points. These are compared to the respective statistical estimates from the
5000 scenario samples.
III. Results
We evaluated the described methodology on three patient cases – an intracranial,
paraspinal, and prostate patient. Information about the datasets, treatment plans and the
assumed input uncertainty model can be found in Table 1.
III.A. Proof of work – computation on patient data
Figure 1 compares sample mean and standard deviation of DVHs to the respective
analytical computations with Equations (7) to (11) for treatments with 30 fractions.
For the prostate case, the sampled and analytically computed mean DVH and its stan-
dard deviation yield good agreement for both target and OAR. For the intracranial case,
especially the curves illustrating standard deviation seem to exhibit larger differences. How-
ever, a closer look reveals that the differences originate from both discrepancies of the mean
and the standard deviation estimates.
To better quantify the differences between the analytical computation and the sample
reference, Figure 2 summarizes the absolute difference in relative volume for all patients
grouped by (1) mean and standard deviation, (2) targets and OARs, and (3) 1 and 30 fraction
treatments. Differences between analytical and sample computations are, in general, larger
for targets than for OARs. For the OARs, the evaluation for multiple fractions shows an
increase in accuracy. This does not seem to transfer to targets, where, although the number
of points with minimal difference (< 0.001) also increases, a stronger tail to higher differences
is present. In general, more outliers, i. e., single DVH-points with large difference, can be
observed when performing the calculations for a treatment in 30 fractions.
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Figure 1: Analytically computed expectation value and standard deviation of DVHs of a target volume and OAR
for each of the three patient cases, compared to the respective sample mean and standard deviation. For the
sampling benchmark, 100 treatments were simulated by multivariate normal sampling using the systematic errors
from Table 1 as standard deviation, while for each treatment taking 30 fraction samples based on the random
component.
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Figure 2: Histograms (bin width: 0.001) of the absolute differences observed between the mean and standard
deviation of all DVH-points computed analytically and via random sampling for all patients. (a,b) show the
analysis for all evaluated targets in all patients, while (c,d) display it for all evaluated OARs.
III.B. Validation of model and analytical computations
III.B.1. Distribution of single DVH-points
Figure 3 shows normalized histograms of two DVH-points (one evaluated at 57Gy for the
target and one at 30Gy for the brainstem of the intracranial case), comparing the samples
from the dose scenarios and from the multivariate normal approximation. Their respec-
tive approximations with a normal distribution visualize differences between the respective
moments of the DVH-point’s probability distribution: in the CTV, the re-sampled mean
underestimates the DVH at 57Gy by a volume fraction of 4%, whereas in the brainstem
difference between the mean / expected values is negligible. The opposite holds true for the
computed standard deviation.
The analytically computed expectation value and variance of the respective DVH-points
shows no significant difference to the statistical moments obtained from the re-sampled
data. This is expected, since the analytical computations are mathematically exact and only
negligible numerical inaccuracy is introduced when evaluating the univariate and bivariate
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Figure 3: Probability distribution over DVH-points evaluated at dˆ = 57Gy in the CTV (a) and at 30Gy in the
brainstem (b) of the intracranial case. The histograms show the distribution from the 5000 dose scenarios and the
5000 dose distributions re-sampled under assumption (15). NS represents a normal distribution parameterized
from sample mean and variance from the 5000 DVHs obtained from the scenario samples, NR has ben similarly
computed from the re-sampled scenarios. NA parameterizes a normal distribution based on the analytical (APM)
computation of DVH-point expectation and variance, and BA uses the same values to parameterize a beta
distribution. The vertical lines indicate the respective expected/mean values, with the dashed black line giving
the nominal value.
normal CDF.
The Gaussian approximation is not bound to the volumetric interval [0, 1], and thus
would assign non-zero probability to non-existing, e. g., negative, volume fractions. Figure 3
thus shows corresponding approximations with beta distributions, whose shape parameters
are obtained from Equations (23) and (24) using analytically computed expectation and
variance of the DVH-point. This leads to a physically more reasonable distribution which is
further backed by the Q-Q plots comparing the quantiles of the normal and beta approxi-
mation to the empirical quantiles in Figure 4.
Figures 4a and 4b underline the problem of the infinite support of the normal distri-
bution, i. e., unphysical quantiles exist in the theoretical normal model. This goes hand in
hand with an especially pronounced disagreement between theoretical and empirical quan-
tiles approaching the boundaries of the interval [0, 1], but also concerns possible skewness
(compare Figures 3b and 4b) or excess kurtosis of the distribution (Figures 3a and 4a). These
disagreements are reduced using a beta distribution. Especially the evaluated DVH-point
in the brainstem in Figure 4d shows near perfect agreement with the empirical quantiles.
For all four evaluations in Figure 4, however, near perfect agreement is achieved for “inner”
quantiles, i. e., the first and third quartile.
III.B.2. Evaluation of cumulative probabilities
Next, we assess the accuracy of complete α-DVHs by comparing α-DVHs computed
from the quantile functions of the respective probability distribution parameterized from
the analytical computations with empirical quantiles over the full DVH. Furthermore we
compare to the previous attempt of analytical computation of α-DVHs27 as laid out in
III. Results
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Section II.C.2.
Figure 5 shows the respective comparisons of analytically computed DVCMs to DVCMs
obtained from sample statistics (compare Equation (5)). The α-DVHs in Figures 5a and 5b
computed with Equation (14), i. e., the method from Cutanda Henríquez and Vargas Cas-
trillón27, show significant differences to the corresponding reference α-DVHs from sampling.
In Figures 5c and 5d, the probabilities within the empirical DVCMs show large differ-
ences when compared to DVCMs computed with the CDF from the Gaussian approximation,
especially near full volume coverage and near zero volume coverage, where the approximated
CDF exhibits differences of up to ±0.2. This is to be expected due to the infinite support
of the normal distribution, and therefore the agreement is much better with the beta ap-
proximation in Figures 5e and 5f (overall the deviation is more than halved compared to
the normal approximation). This transfers to the computation of α-DVHs based on the
quantile function of the beta distribution, similarly showing better agreement than with the
assumption of normally distributed DVH-points. Overall, our explicit parametrization and
evaluation of quantile functions of either normal or especially beta distributions outperforms
the previously published method27 (compare Section II.C.2).
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Figure 4: Quantile-quantile plots comparing empirical quantiles (y-axis) for the data (green) to quantiles from the
hypothesized normal (a,b) and beta (c,d) distributions (x-axis) obtained from analytical moment computations
(red). The thicker green and yellow lines span the 5%–95% and 25%–75% quantiles, respectively. In each plot
the gray area additionally enclose “physically feasible” volumes in [0, 1]. CTV and brainstem of the intracranial
case are shown for the same DVH-points as in Figure 3. The data is based on the 5000 dose scenario samples for
a single fraction.
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Figure 5: Evaluation of probabilities and α-DVHs obtained through scenario sampling and analytical computations.
(a) and (b) show empirical DVCMs (indexed with S) obtained from the 5000 dose scenarios, where the color
indicates the local value of the CDF of the respective DVH-point. Corresponding α-DVHs were derived, based on
sampling (S) and on Cutanda Henríquez and Vargas Castrillón27 (H). For (c) and (d) the difference of DVCMN ,
a DVCM constructed from the normal parameterization, to DVCMS has been evaluated with corresponding α-
DVHs obtained from the normal quantile function. (e,f) provide a similar analysis using DVCMB and α-DVHs
(B) with the beta parameterization.
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IV. Discussion
The very core of this work is the description of an analytical model that can com-
pute statistical moments of DVH-points for arbitrary probability distributions over the dose
distribution. The only requirement is that the dose distribution follows/obeys a probabil-
ity distribution function where the marginal CDFs can be evaluated. Hence, we provide a
mathematically exact formulation of the moments which eliminates statistical uncertainty (in
particular in combination with APM-based uncertainty quantification18,22); if the probability
distribution over dose is known, the respective moments can be exactly computed.
In our initial analysis, a multivariate normal distribution was assumed based on expected
dose and its covariance obtained from a probabilistic dose calculation employing APM, which
we compared to a sampling benchmark. Most of the analytically computed expected and
standard deviations of the investigated DVHs lied within ±1.5% difference in volume from
the sampling benchmark. Evaluating the same model for a larger number of fractions showed
that especially for the OARs, more values cluster around the small differences.
Those differences between analytical model and sampling benchmark mainly stem from
the assumed probability distribution over the dose distribution. It is clear that the multivari-
ate normal assumption for dose uncertainty used throughout this work does not reflect every
detail of reality perfectly. This is directly obvious because dose cannot be negative while
the normal distribution has infinite support. But also deformations and anatomical varia-
tions, the non-linearity of dose deposition, and the so far not captured complexity of input
uncertainty suggest that “real” dose uncertainty will most likely manifest as non-Gaussian
probability distributions differing across heavily interdependent voxels. For parametrizing
such models, an appropriate family of probability distributions that reasonably models vari-
ation in voxel doses would have to be selected for which correlations could then, for example,
be modeled with copulas. While finding a suitable probabilistic model accurately describing
dose distributions under uncertainty is beyond the scope of this work, our method would
also be compatible with such advanced models, since it only requires that some form of mul-
tivariate CDF can be computed. This includes non-Gaussian analytical as well as empirical
CDFs. In doing so our model has the advantage to preserve the mathematical connection
between dose DVH-variation which would not be accessible when sampling DVH-scenarios
themselves.
Despite the inaccuracy inherent to our choice of a multivariate normal distribution, it
served as good initial proof of concept for the presented method. The multivariate normal
parametrization allowed straightforward resampling of dose scenarios to demonstrate the
exactness of the closed-form solution. The validation with results from sampled dose cubes
and DVHs on the three patient cases showed that despite using this physically flawed model,
we still obtain reasonable results, especially for the prostate and paraspinal case. The larger
deviations in the intracranial case may be attributed to the smaller VOIs compared to
the other two cases. The above discussed observation that fractionation seems to decrease
the difference in most voxels might be attributed to a more Gaussian shaped probability
distribution of dose uncertainty in the context of fractionation (as also indicated within Ref.
7).
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Our model describes moments of the DVH-points’ probability distributions and not the
probability distribution over the full DVHs. Therefore it is not directly possible to exactly
compute confidences on actual realizations of the full DVH. It is, however, possible to use
the computed moments to parameterize distributions over DVH points. In our evaluations
based on expected DVH-points and their standard deviation, usage of normal distributions
was a first obvious choice. To some extent it may be surprising that this yielded acceptable
results within few volume percent difference to the sampling benchmark: The choice of a
normal distribution (with infinite support) is in this case of a volume fraction, which can
take only values in the interval [0, 1], similarly physically unreasonable as in the case of the
dose distribution. A more plausible (concerning the support interval) parameterization was
found using a beta distribution. However, both distributions do not represent a mathemati-
cally exact model. Interpreting the calculation of a DVH-point as a series of Bernoulli trials
(similar to Ref. 25, see Section II.B.2), suggests parameterization with a Binomial distribu-
tion in the case of independently and identically distributed individual voxel doses. Still,
assuming independence of voxels would not be realistic. More suitable correlated binomial
models35 make specific assumptions and are computationally demanding, rendering them not
applicable for our purpose. Nevertheless, assuming a beta distribution (or even a normal dis-
tribution), which is parameterized by mean and standard deviation for the DVH-point, could
facilitate uncertainty propagation through models that build on DVHs itself, e. g. in deriving
biologically effective dose,36 or refining the statistical models for optimization purposes.19
In comparison to the previous works25–27, our methodology directly reproduced their
model for the expectation value of DVH-points.25 Our approach using integration directly
generalizes to higher moments like covariance, while their model only yielded upper bounds
on the variance because correlations between voxels were not explicitly included. Yet, despite
the lack of an uncertainty model considering covariance in dose, they formulated confidence
bounds, i. e., α-DVHs.27 Those were, however, in stark disagreement with the sampling
benchmark (and thence our model). This may mainly be attributed to neglecting the con-
tribution of (in)dependencies between voxels in the derivations. The difference of Equa-
tion (14) to a “true” confidence of dose over coverage of a volume fraction may be shown by
the following gedankenexperiment: Let us assume all V voxels in a VOI v are independently
normally distributed with a mean value of dˆ and identical variances, and therefore exhibit-
ing Fdi(dˆ) = 0.5 in all voxels i ∈ v. In this setup, one can see that the median DVH-point
at dˆ takes the value 0.5. Yet, plugging this into Equation (14) with again α = 0.5 yields
α-DVHHC(dˆ) = 1
V
·V ·Θ(1−0.5−0.5) = 1 6= 0.5 (depending on the definition of the Heaviside-
step). Furthermore, in this case Equation (14) exhibits a sharp “step” around dˆ: For smaller
doses dˆ− , the argument of the step function in Equation (14) becomes negative and there-
fore resulting in α-DVH(dˆ− ) = 1, while for larger doses it becomes α-DVH(dˆ− ) = 0. For
the assumed independently distributed model, however, a smooth decrease of the median
DVH around dˆ is expected, whereas the step would be correctly reproduced when assuming
perfectly correlated voxels. Instead we suggest to interpret their result as the “fraction of
voxels whose probability of exceeding dˆ independently from each other is larger than 1−α”.
Such a quantity, however, does not have a palpable clinical interpretation.
The applicability of a method that propagates uncertainty from dose to DVHs in terms
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of treatment planning might not be directly obvious. As discussed in Section I, uncertainty
quantification usually relies on sampled (stochastic approach) or selected (worst-case ap-
proach) dose scenarios, which can directly be used to obtain similar uncertainty information
about the DVH. However, the analytical probabilistic method presented here provides a
closed-form, continuous relationship between dose uncertainty and DVH-uncertainty, which
can be useful in treatment planning.
For optimization purposes with probabilistic constraints, the method facilitates the use
of continuous differentiable functions, which “fill the gap” between empirical samples, and
could possibly enable exact definition of the “allowed” probability that certain clinical con-
straints are failing. There, using the parameterization of the probability distribution over
a DVH-point, we now have functional access to the probability that a specific dose level is
covered with a certain probability via the α-DVH and its analytical dependence on mean
and covariance of the dose (instead of nominal dose as for conventional non-probabilisitc
objectives).37,38 Using this information for planning would extend widely used margin prin-
ciples,39,40 which are themselves defined based on demanding tumor coverage with a desired
probability for a given dose level. Compared to common robust approaches where the worst
case is dynamically found from a discrete pre-defined uncertainty subset in the input vari-
ables, an analytical confidence constraint based on α-DVHs captures the full uncertainty
space and allows for definition of the desired robustness on the relevant endpoint. For exam-
ple, 90% probability to cover a tumor with the 95% of the prescribed dose could reproduce
common margin assumptions also for anatomically complex cases where margins break down,
while at the same time other probabilistic or nominal endpoints could be optimized. Since
these objectives (or also constraint functions) continue to be functions of mean and covari-
ance of dose, optimization would remain possible using conventional (quasi-)Newton opti-
mizers. This, however, comes at the cost of deriving the arguably complex gradients (w.r.t.
dose mean & covariance), which could be mitigated by using automatic differentiation,41
accompanied by a computationally challenging, yet “embarrassingly parallel” (co)variance
computation.37,38 Further, the role of model inaccuracy in such a probabilistic optimization
approach would need to be further investigated—Wieser et al.42, however, suggest that the
assumption of normal distributions in probabilistic optimization still enables mitigation of
dose uncertainties even if the “real” distribution differs substantially. A full analysis of com-
putational performance and resulting dose distributions of such an optimization approach
would exceed this manuscript and may be part of a future study.
Further, the probabilistic model only requires the dose’s probability distribution and
is independent of the method used to obtain it. This allows its general application, e. g.,
in (retrospective) plan analyses or in combination with sampling-based stochastic optimiza-
tion approaches. For plan analysis and comparison, the closed-form connection of dose and
DVH-uncertainty could be used to observe how higher dose uncertainty (simulated by scal-
ing covariance in desired voxels, for example) would impact the DVH and therefore target
coverage. When relying on sample statistics for the dose instead of a probabilstic dose calcu-
lation, the parameterizations can be useful to extrapolate to areas not covered by samples.
Additionally, the method could also be used in scenarios where computation of uncertainties
statistically is no longer possible (e. g. when analysing an older cohort) based on assumptions
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over the dose probability distributions while still retaining the mathematical link between
dose and DVH probabilities, which may be useful for machine learning applications investi-
gating plan uncertainties.
And last but not least, the generral concept does not only apply to the computation
of DVH points. As already indicated by Wahl37, the concept may—given mathematical
efforts—be extended to other plan quality metrics as mean dose or equivalent uniform dose
(EUD), or distinct treatment planning objective and constraint functions.
V. Conclusion
We presented a method to calculate moments of the probability distribution over DVH-
points given a known probability distribution over the dose distribution. The resulting
analytical model corrects and generalizes previous attempts and can be readily combined
with every method able to quantify a probability distribution over dose of either empirical
or probabilistic nature.
We successfully benchmarked the model against excessive sampling (with and without
fractionation), proving mathematical correctness and good agreement even with unrealistic
but common assumptions for probability distributions within the computational pipeline.
The methodology can serve as blueprint for future models on other QIs and can provide
a generalizable framework for confidence-constrained probabilistic treatment plan optimiza-
tion.
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Appendix
A. Beta distribution
Suppose a random variable X follows a beta distribution, i. e., X ∼ B(a, b) with shape
parameters a and b.
Within the interval x ∈ [0, 1] (for a > b > 1, x ∈ (0, 1) otherwise) its probability density
function (PDF) fX(x) is given by
fX(x) =
1
B(a, b)
xa−1(1− x)b−1 (19)
where the normalization B(a, b) is the beta-function.
The CDF
FX(x) = Ix(a, b) (20)
requires evaluation of the regularized incomplete beta-function Ix.
Expectation and variance of X are then given by
E [X] =
a
a+ b
, (21)
Var [X] =
ab
(a+ b+ 1)(a+ b)2
=
E [X]2 b
a2 + ab+ a
. (22)
The shape parameters a and b can be inferred from sample statistics, i. e., the sample
mean x¯ and the sample variance σ¯2, with the method of moments based on Equations (21)
A. Beta distribution
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and (22) for σ¯2 < x¯(1− x¯):
aˆ = x¯
(
x¯(1− x¯)
σ¯2
− 1
)
, (23)
aˆ = (1− x¯)
(
x¯(1− x¯)
σ¯2
− 1
)
= x¯(1− x¯)aˆ . (24)
B. Patient Data Information
Table 1: Information on the three patient datasets used for evaluation (similar to Wahl et al.22).
patient intra-cranial para-spinal prostate
beam angles 60◦, 120◦ 135◦, 180◦, 225◦ 90◦, 270◦
prescribed dose 60Gy 60Gy 70Gy (76Gy)
beamlet distance 3mm 4mm 5mm
#beamlets 1705 13274 6803
resolution (1.2× 1.2× 3)mm3 (3× 3× 3)mm3 (2× 2× 3)mm3
setup error [std. dev.] (1mm)sys + (2mm)rand (1mm)sys + (2mm)rand (1mm)sys + (3mm)rand
range error [std. dev.] (3.5%)sys + (1mm)rand (3.5%)sys + (1mm)rand (3.5%)sys + (1mm)rand
C. Generalized model for the ν-th moment of a
probability distribution over a DVH-point
Using multi-index notation with the multi-index κ = (κ1, κ2, . . . , κV ) ∈ NV0 and by
definition of a multi-indexed Heaviside step Θκ(d˜ − dˆ) = ∏ni=1 Θ(d˜i − dˆ)κi , one can pro-
vide a compact general formula to compute the ν-th non-central moment of the probability
distribution of a DVH-point, i. e.,
E
[
DVH(dˆ;d)ν
]
=
∫
Rn
1
V ν
∑
|κ|=ν
(
ν
κ
)
Θκ(d˜− dˆ)fd(d˜)dd˜
=
1
V ν
∑
|κ|=ν
(
ν
κ
)[
1− Fdκ(dˆ · 1ν)
] (25)
where Fdκ(dˆ · 1ν) corresponds to the evaluation of a ν-variate marginal probability and
1ν ∈ Rν is a vector with each of the ν components equal to 1. For example, in the case of
ν = 3 and V = 4, given an index combination κ = (2, 0, 1, 0) (satisfying the sum condition
|κ| = ν = 3), the trivariate probability Fd1;1;3((dˆ, dˆ, dˆ)T ) needs to be evaluated. Note that
the possible “doubling” of an index (i. e., κi > 1) can also be eliminated in the underlying
integral using Θ(x)κi = Θ(x). This reduces the given example to an evaluation of a bivariate
probability Fd1;3((dˆ, dˆ)T ) = Fd1;1;3((dˆ, dˆ, dˆ)T ).
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